These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35244999)

  • 1. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
    Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers.
    Yun SJ; Jeong P; Kang HW; Kim YH; Kim EA; Yan C; Choi YK; Kim D; Kim JM; Kim SK; Kim SY; Kim ST; Kim WT; Lee OJ; Koh GY; Moon SK; Kim IY; Kim J; Choi YH; Kim WJ
    Int Neurourol J; 2015 Jun; 19(2):74-84. PubMed ID: 26126436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer.
    Byun YJ; Piao XM; Jeong P; Kang HW; Seo SP; Moon SK; Lee JY; Choi YH; Lee HY; Kim WT; Lee SC; Cha EJ; Yun SJ; Kim WJ
    Investig Clin Urol; 2021 May; 62(3):340-348. PubMed ID: 33834642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer.
    Byun YJ; Kang HW; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Lee SC; Yun SJ; Kim WJ
    Prostate Int; 2022 Mar; 10(1):1-6. PubMed ID: 35155300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
    Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of miRNAs in urine of prostate cancer patients.
    Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
    Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics.
    Wang H; Yang L; Mi Y; Wang Y; Ma C; Zhao J; Liu P; Gao Y; Li P
    Contrast Media Mol Imaging; 2022; 2022():6094409. PubMed ID: 35935308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
    Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
    Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
    Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
    Jin W; Fei X; Wang X; Chen F; Song Y
    J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
    Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
    Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A circulating miRNA assay as a first-line test for prostate cancer screening.
    Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
    Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia.
    Sancer O; Koşar PA; Tefebaşı MY; Ergün O; Demir M; Koşar A
    Turk J Med Sci; 2022 Jun; 52(3):788-795. PubMed ID: 36326314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Urinary miRNAs in the Diagnosis, Management and Follow- Up of Prostatic Cancer.
    Ziogou A; Giannakodimos A; Giannakodimos I
    Microrna; 2023; 12(2):83-86. PubMed ID: 36999432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA-21 as High Potential Prostate Cancer Biomarker in Prostate Cancer Patients in Indonesia.
    Gunawan RR; Astuti I; Danarto HR
    Asian Pac J Cancer Prev; 2023 Mar; 24(3):1095-1099. PubMed ID: 36974566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases.
    Dülgeroğlu Y; Eroğlu O
    Microrna; 2020; 9(4):303-309. PubMed ID: 33155933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.